KYNB
Kyntra Bio, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.30M
P/E Ratio
—
EPS
$-13.99
Beta
1.04
52W High
$12.60
52W Low
$4.85
50-Day MA
$7.03
200-Day MA
$8.93
Dividend Yield
—
Profit Margin
2199.00%
Forward P/E
61.35
PEG Ratio
—
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $7.44M |
| Gross Profit (TTM) | $-20.49M |
| EBITDA | $-43.74M |
| Operating Margin | -369.10% |
| Return on Equity | 0.00% |
| Return on Assets | -20.20% |
| Revenue/Share (TTM) | $1.84 |
| Book Value | $-10.82 |
| Price-to-Book | 80.40 |
| Price-to-Sales (TTM) | 3.80 |
| EV/Revenue | 10.57 |
| EV/EBITDA | 44.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.50% |
| Shares Outstanding | $4.05M |
| Float | $3.56M |
| % Insiders | 2.03% |
| % Institutions | 25.55% |
Historical Volatility
HV 10-Day
42.52%
HV 20-Day
34.86%
HV 30-Day
36.50%
HV 60-Day
41.90%
HV Rank
0.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($43.00 target)
1
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026